Differential expression of new splice variants of the neurotensin receptor 1 gene in human prostate cancer cell lines

Peptides

Volumn 31, Issue 2, 2010, Pages 242-247

  Almeida, Teresa A ^a   Rodriguez, Yurena ^a   Hernández, Mariano ^a   Reyes, Ricardo ^a   Bello, Aixa R ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Alternative splicing; Cancer; Neurotensin; Neurotensin receptor 1; RT PCR

Indexed keywords

ANDROGEN; ISOPROTEIN; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL STRAIN LNCAP; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; RNA SPLICING; TISSUE SECTION;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CLONING, MOLECULAR; CODON, TERMINATOR; DNA PRIMERS; EXONS; GENE EXPRESSION; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, NEUROTENSIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICE SITES; RNA, MESSENGER; SEQUENCE ALIGNMENT;

EID: 73949109143     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.12.007     Document Type: Article

References (26)

1. Botto J.M., Sarret P., Vincent J.P., and Mazella J. Identification and expression of a variant isoform of the levocabastine-sensitive neurotensin receptor in the mouse central nervous system. FEBS Lett 400 (1997) 211-214
2. Boudin H., Grauz-Guyon A., Faure M.P., Forgez P., Lhiaubet A.M., Dennis M., et al. Immunological recognition of different forms of the neurotensin receptor in transfected cells and rat brain. Biochem J 305 (1995) 277-283
3. Carraway R.E., Gui X., and Cochrane D.E. Ca2+ channel blockers enhance neurotensin (NT) binding and inhibit NT-induced inositol phosphate formation in prostate cancer PC3 cells. J Pharmacol Exp Ther 307 (2003) 640-650
4. Carraway R.E., and Hassan S. Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress. Regul Pept 7 (2007) 140-153
5. Carraway R.E., and Plona A.M. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides 27 (2006) 2445-2460
6. Chabry J., Botto J.M., Nouel D., Beaudet A., Vincent J.P., and Mazella J. Thr-422 and Tyr-424 residues in the carboxyl terminus are critical for the internalization of the rat neurotensin receptor. J Biol Chem 270 (1995) 2439-2442
7. Elek J., Pinzon W., Park K.H., and Narayanan R. Relevant genomics of neurotensin receptor in cancer. Anticancer Res 20 (2000) 53-58
8. Hermans E., Octave J.N., and Maloteaux J.M. Interaction of the COOH-terminal domain of the neurotensin receptor with a G protein does not control the phospholipase C activation but is involved in the agonist-induced internalization. Mol Pharmacol 49 (1996) 365-372
9. Kitabgi P. Functional domains of the subtype 1 neurotensin receptor (NTS1). Peptides 27 (2006) 2461-2468
10. Najimi M., Gailly P., Maloteaux J.M., and Hermans E. Distinct regions of C-terminus of the high affinity neurotensin receptor mediate the functional coupling with pertussis toxin sensitive and insensitive G-proteins. FEBS Lett 512 (2002) 329-333
11. Oakley R.H., Laporte S.A., Holt J.A., Barak L.S., and Caron M.G. Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis. J Biol Chem 276 (2001) 19452-19460
12. Perron A., Sarret P., Gendron L., Stroh T., and Beaudet A. Identification and functional characterization of a 5-transmembrane domain variant isoform of the NTS2 neurotensin receptor in rat central nervous system. J Biol Chem 280 (2005) 10219-10227
13. Reubi J.C., Mäcke H.R., and Krenning E.P. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46 Suppl. 1 (2005) 67S-75S
14. Reubi J.C., Waser B., Schaer J.C., and Laissue J.A. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int J Cancer 82 (1999) 213-218
15. Seck T., Pellegrini M., Florea A.M., Grignoux V., Baron R., Mierke D.F., et al. The delta e13 isoform of the calcitonin receptor forms a six-transmembrane domain receptor with dominant-negative effects on receptor surface expression and signaling. Mol Endocrinol 19 (2005) 2132-2144
16. Seethalakshmi L., Mitra S.P., Dobner P.R., Menon M., and Carraway R.E. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 31 (1997) 183-192
17. Sehgal I., Powers S., Huntley B., Powis G., Pittelkow M., and Maihle N.J. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA 91 (1994) 4673-4677
18. Skrzydelski D., Lhiaubet A.M., Lebeau A., Forgez P., Yamada M., Hermans E., et al. Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 64 (2003) 421-429
19. Sun Y.J., Maeno H., Aoki S., and Wada K. Mouse neurotensin receptor 2 gene (Ntsr2): genomic organization, transcriptional regulation and genetic mapping on chromosome 12. Brain Res Mol Brain Res 95 (2001) 167-171
20. Tichopad A., Pfaffl M.W., and Didier A. Tissue-specific expression pattern of bovine prion gene: quantification using real-time RT-PCR. Mol Cell Probes 17 (2003) 5-10
21. Venables J.P. Aberrant and alternative splicing in cancer. Cancer Res 64 (2004) 7647-7654
22. Vincent J.P., Mazella J., and Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 20 (1999) 302-309
23. White J.F., Grodnitzky J., Louis J.M., Trinh L.B., Shiloach J., Gutierrez J., et al. Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction. Proc Natl Acad Sci USA 104 (2007) 12199-12204
24. Williams D.M., Koduri S., Li Z., Hankins W.D., and Poola I. Primer design strategies for the targeted amplification of alternatively spliced molecules. Anal Biochem 271 (1999) 194-197
25. Yamada M., Yamada M., Watson M.A., and Richelson E. Deletion mutation in the putative third intracellular loop of the rat neurotensin receptor abolishes polyphosphoinositide hydrolysis but not cyclic AMP formation in CHO-K1 cells. Mol Pharmacol 46 (1994) 470-476
26. http://www.expasy.org